About Sierra Oncology, Inc. (SRRA) — Dividend Analysis 2026
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Is SRRA a good dividend investment in 2026?
SRRA offers a 3.64% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
SRRA DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your SRRA portfolio grows to $14.3K vs $13.6K without reinvestment. This is the compound interest effect in action.
SRRA dividend growth history & forecast
SRRA has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 3.64%.
Company generates negative FCF ($-79M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.1B → -0.1B → -0.1B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 SRRA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SRRA.
Gross yield
3.64%
Tax rate
15.00%
After-tax yield
3.09%
Real yield (−CPI)
0.29%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
3.64%
0.84%
$364 / yr
🇺🇸 US Taxable (15%) ✓
15%
3.09%
0.29%
$309 / yr
🇺🇸 US Taxable (20%)
20%
2.91%
0.11%
$291 / yr
🇬🇧 UK ISA
0%
3.64%
0.84%
$364 / yr
🇬🇧 UK Taxable
8.75%
3.32%
0.52%
$332 / yr
🇨🇦 TFSA
0%
3.64%
0.84%
$364 / yr
🇨🇦 CA Taxable
25%
2.73%
-0.07%
$273 / yr
🇦🇺 Super (pension)
15%
3.09%
0.29%
$309 / yr
🇦🇺 AU Taxable
30%
2.55%
-0.25%
$255 / yr
🇩🇪 DE Taxable
26.375%
2.68%
-0.12%
$268 / yr
🇫🇷 FR Taxable
30%
2.55%
-0.25%
$255 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SRRA Income Goal & Break-Even
Dividend Break-Even
33yr
Years for dividends to fully repay your SRRA investment of $54.99/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$3.6K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$1.1K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in SRRA for:
Shares needed
14,118
Capital required
$776,349
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SRRA Dividend Payment Schedule
SRRA pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 SRRA vs Healthcare Benchmarks
How SRRA compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+0.84% vs sectorBetter
SRRA
3.64%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
SRRA
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
SRRA
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SRRA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SRRA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Vivo Opportunity, LLC
director, 10 percent owner:
D-Return
2022-07-01
75,749
$13.20
$999.9K
Vivo Opportunity, LLC
director, 10 percent owner:
D-Return
2022-07-01
431,947
$55.00
$23.76M
ORBIMED ADVISORS LLC
director, 10 percent owner:
D-Return
2022-07-01
170,437
$13.20
$2.25M
ORBIMED ADVISORS LLC
director, 10 percent owner:
D-Return
2022-07-01
226,704
$55.00
$12.47M
Ashiya Mona
director, 10 percent owner:
D-Return
2022-07-01
170,437
$13.20
$2.25M
Ashiya Mona
director, 10 percent owner:
D-Return
2022-07-01
1,500
$13.87
$20.8K
Ashiya Mona
director, 10 percent owner:
D-Return
2022-07-01
6,000
$18.11
$108.7K
Ashiya Mona
director, 10 percent owner:
D-Return
2022-07-01
6,874
$13.98
$96.1K
Ashiya Mona
director, 10 percent owner:
D-Return
2022-07-01
226,704
$55.00
$12.47M
Sinclair Andrew
director
D-Return
2022-07-01
6,000
$18.11
$108.7K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SRRA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →